Report from Annual General Meeting of Vitrolife AB

Report from Annual General Meeting of Vitrolife AB

At Vitrolife's Annual General Meeting yesterday, April 27, the
following, amongst other things, was decided:

  · The Board's proposed dividend of SEK 0.60 for the financial year
2010 was approved. May 2, 2011 was adopted as the record day.

  · Changes of the Articles of Association entailing, among other
things, auditors mandate period to be three years, and notice of a
General Meeting of shareholders shall be given to shareholders through
an announcement in the Swedish Official Gazette (Post- och Inrikes
Tidningar) and on the company's website. That notice has been given
shall be announced in Dagens Industri.

  · Re-election of Board members Patrik Tigerschiöld, Fredrik Mattsson,
Madeleine Olsson-Eriksson, Tord Lendau, Maris Hartmanis and Barbro
Fridén, in accordance with the election committee's proposal. Patrik
Tigerschiöld was re-elected Chairman of the Board.

  · Re-election of Öhrlings PricewaterhouseCoopers, with the authorized
accountant Birgitta Granquist as head auditor, as auditor for a period
of three years.

  · An increase of the remuneration to the members of the Board
totalling SEK 770,000 (700,000), of which SEK 220,000 (200,000) is
allocated to the Chairman of the Board and SEK 110,000 (100,000) to each
of the other Board members. Fees to the auditor shall be paid in
accordance with reasonable invoicing.

  · Authorization for the Board, for the time up until the next Annual
General Meeting and on one or more occasions, to take a decision on the
issue of a maximum of 1,950,000 shares in total, corresponding to
approximately 10 percent of the company's share capital.

  · The Board was authorized to take a decision, up until the next
Annual General Meeting and on one or more occasions, with regard to the
acquisition and transfer of the company's own shares, at the most 10
percent of the company's shares.

  · The proposed principles for remuneration and other conditions of
employment for the senior management were approved.

Gothenburg, April 28, 2011
VITROLIFE AB (Publ)
The Board

Queries should be addressed to:
Magnus Nilsson, CEO, phone +46 31 721 80 61
Anne-Lie Sveder, CFO, phone +46 31 721 80 13

________________________________________________________________________
________________

Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for
the preparation, cultivation and storage of human cells, tissue and
organs. The company has business activities within three product areas:
Fertility, Transplantation and Stem Cell Cultivation. The Fertility
product area works with nutrient solutions (media), cryopreservation
products and advanced consumable instruments such as needles and
pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain
organs outside the body in order to select usable organs and keep them
in optimal condition while waiting for transplantation. The Stem Cell
Cultivation product area works with media and instruments to enable the
use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 220 employees and its products are
sold in more than 85 markets. The company is headquartered in
Gothenburg, Sweden, and there are subsidiaries in USA, Australia,
France, Italy, United Kingdom and Japan. Production facilities are
located in Sweden and the USA. The Vitrolife share is listed on NASDAQ
OMX Stockholm, Small Cap.

________________________________________________________________________
_________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate
identity number 556354-3452.

Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail:
info@vitrolife.com. Website:
www.vitrolife.com (http://www.vitrolife.com/).

Vitrolife is required to publish the information in this press release
in accordance with the Swedish Securities Market Act. The information
was submitted for publication on Thursday April 28, 2011, at 8.30 a.m.
CET.

This is a translation of the Swedish version of the press release. When
in doubt, the Swedish wording prevails.